Decision Resources Introduces the Only Healthcare Analytics Tool that

  Assesses the Number of Insured Patients Who Have a Specific Disease, but

                               Are Untreated



    WALTHAM, Mass., Aug. 11 /EMWNews/ -- Decision Resources, one of the

world's leading research and advisory firms focusing on pharmaceutical and

healthcare issues, finds that Florida has the highest number of untreated

people with type 2 diabetes who also have prescription (Rx) drug coverage.

This type of information is invaluable to pharmaceutical companies who are

challenged to pinpoint the areas of greatest need for their drugs.



    The new analytic tool from Decision Resources entitled PatientFinder:

Type 2 Diabetes also reveals that West Virginia and Maine have the highest

type 2 diabetes prevalence as a percent of their population. The report

also finds that California has the absolute largest number of untreated

patients (455,000) in part because it has the largest overall population.

But the fact that California has a lower percentage of its population with

Rx drug coverage means that the overall opportunity for market expansion in

this state is less than in other, smaller states.



    Why Pharmaceutical Companies Need this Information



    With the type of information included in PatientFinder, pharmaceutical

organizations can identify the local markets that offer the greatest

opportunity for their branded drug. Companies can identify markets that are

underserved and determine if they should increase direct-to-consumer

advertising, work with the local managed care organizations to increase

awareness of the disease and benefits of their drug or align sales

representatives to maximize market potential.

    About PatientFinder



    PatientFinder is the only healthcare analytics tool that assesses local

markets for expansion opportunity by determining the number of insured

patients in each territory who have the disease but are untreated.

PatientFinder covers each of the 50 U.S. states and 318 U.S. metropolitan

statistical areas (MSAs) and provides:



    -- Disease-specific prevalence numbers for each U.S. state and MSA



    -- Examination of treatment rates for the disease population to create

percent treated and percent untreated estimates by state and MSA



    -- Unique analysis of the untreated population examined through a

filter of Rx benefit coverage. The end result is an estimate of how many

patients are untreated but can afford therapy within each territory -- the

true local measure of opportunity for pharmaceutical companies



    About Decision Resources



    Decision Resources (http://www.decisionresources.com) is a world leader

in market research publications, advisory services and consulting designed

to help clients shape strategy, allocate resources, and master their chosen

markets. Decision Resources is a Decision Resources, Inc. company.



    All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.






    For more information, contact:



    Elizabeth Marshall

    Decision Resources

    781-296-2563

    [email protected]